Merck & Co. (NYSE:MRK) has announced the acquisition of the leading mRNA contract development and manufacturing organization (CDM)), Amptec. The acquisition will enhance Merck’s mRNA development and manufacturing capabilities for its customers to use in...
Merck & Co. (NYSE:MRK) has signed a $356 million supply deal with the US government for the supply of 60,000 to 100,000 doses of its investigational severe COVID-19 treatment. This adds to the government’s arsenal of possible COVID-19 therapies and also that large...
